Skip to main content
Normal View

Cannabis for Medicinal Use

Dáil Éireann Debate, Wednesday - 20 October 2021

Wednesday, 20 October 2021

Questions (259)

Cian O'Callaghan

Question:

259. Deputy Cian O'Callaghan asked the Minister for Health if he will include chronic pain such as that suffered by persons with fibromyalgia as criteria to apply for the medical cannabis access programme; and if he will make a statement on the matter. [51525/21]

View answer

Written answers

The Health Products Regulatory Authority’s “Cannabis for Medical Review Use – A Scientific Review” advised that treatment with cannabis is only permitted under a controlled access programme for the treatment of patients with;

a. Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions whilst under expert medical supervision;

b. Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes whilst under expert medical supervision;

c. Severe, refractory (treatment-resistant) epilepsy that has failed to respond to standard anticonvulsant medications whilst under expert medical supervision.

The HPRA did not consider that the available evidence supported the use of cannabis in other medical conditions.

Subsequently the Minister for Health established an Expert Reference Group to advise on the development of a Medical Cannabis Access Programme. This Group developed detailed Clinical Guidelines for the MCAP to be followed by clinicians, which contained inter alia guidance on  ingredient combinations that are recommended for each of the three indications included in the MCAP

The Department is currently working to commence a new clinical review that will continue the work of the previous clinical expert group. This review will seek to build on evidence found in the earlier study and will assess if there is new information to support the addition of any other clinical indications to the MCAP.

Top
Share